2016
Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children
Parikh S, Kajubi R, Huang L, Ssebuliba J, Kiconco S, Gao Q, Li F, Were M, Kakuru A, Achan J, Mwebaza N, Aweeka FT. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clinical Infectious Diseases 2016, 63: 414-422. PMID: 27143666, PMCID: PMC4946019, DOI: 10.1093/cid/ciw291.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrine treatmentLPV/rRecurrent malariaLumefantrine exposureDrug exposureCritical drug-drug interactionsFirst-line antiretroviral therapy regimensArtemisinin-based combination therapyLopinavir/ritonavirAntiretroviral therapy regimensPlasmodium falciparum malariaHuman immunodeficiency virusDay 7 concentrationsMalaria-endemic regionsDrug-drug interactionsAntimalarial exposureAntimalarial componentPharmacokinetic samplingArtemether-lumefantrineFalciparum malariaClinical outcomesDosing regimensTherapy regimensImmunodeficiency virusCombination therapy
2015
The epidemiological impact of HIV antiretroviral therapy on malaria in children
Greenhalgh S, Ndeffo M, Galvani AP, Parikh S. The epidemiological impact of HIV antiretroviral therapy on malaria in children. AIDS 2015, 29: 473-482. PMID: 25486414, PMCID: PMC4391884, DOI: 10.1097/qad.0000000000000550.Peer-Reviewed Original ResearchConceptsHIV protease inhibitorsRecurrent malariaMalaria transmissionAntiretroviral therapyArtemether-lumefantrineAnnual incidenceProtease inhibitorsFirst-line antiretroviral regimenFirst-line antiretroviral therapyArtemether-lumefantrine treatmentHIV-negative childrenFirst-line antimalarialsHIV prevalence settingsHIV antiretroviral therapyRecent clinical trialsHIV prevalence levelsMalaria transmission settingsMalaria transmission intensityAntiretroviral regimenAntimalarial treatmentHIV prevalenceProphylactic effectPrevalence settingsClinical trialsHealth burden
2014
Efficacy and Day 7 Plasma Piperaquine Concentrations in African Children Treated for Uncomplicated Malaria with Dihydroartemisinin-Piperaquine
Zongo I, Somé FA, Somda SA, Parikh S, Rouamba N, Rosenthal PJ, Tarning J, Lindegardh N, Nosten F, Ouédraogo JB. Efficacy and Day 7 Plasma Piperaquine Concentrations in African Children Treated for Uncomplicated Malaria with Dihydroartemisinin-Piperaquine. PLOS ONE 2014, 9: e103200. PMID: 25133389, PMCID: PMC4136730, DOI: 10.1371/journal.pone.0103200.Peer-Reviewed Original ResearchConceptsDHA-PQRecurrent malariaDaily dosePlasma concentrationsSingle-arm open-label trialHigher median plasma concentrationsFalciparum malaria treatmentMedian daily dosePharmacokinetics of piperaquineRate of recrudescenceOpen-label trialUncomplicated falciparum malariaMedian plasma concentrationVenous plasma concentrationsSuccessful treatment outcomeDihydroartemisinin-PiperaquineExploratory endpointsParasitological efficacyPiperaquine concentrationsUncomplicated malariaOverall recurrenceYounger patientsFalciparum malariaClinical efficacyCombination therapy
2013
Pharmacokinetic Predictors for Recurrent Malaria After Dihydroartemisinin-Piperaquine Treatment of Uncomplicated Malaria in Ugandan Infants
Creek DJ, Bigira V, McCormack S, Arinaitwe E, Wanzira H, Kakuru A, Tappero JW, Sandison TG, Lindegardh N, Nosten F, Aweeka FT, Parikh S. Pharmacokinetic Predictors for Recurrent Malaria After Dihydroartemisinin-Piperaquine Treatment of Uncomplicated Malaria in Ugandan Infants. The Journal Of Infectious Diseases 2013, 207: 1646-1654. PMID: 23447696, PMCID: PMC4318925, DOI: 10.1093/infdis/jit078.Peer-Reviewed Original ResearchConceptsPiperaquine concentrationsRecurrent malariaDay 7TMP-SMXDihydroartemisinin-piperaquine treatmentPK/PD studiesTMP-SMX prophylaxisTrimethoprim-sulfamethoxazole prophylaxisTime of presentationPK/PD dataYears of ageYoung childrenPiperaquine exposureUgandan infantsUncomplicated malariaMalaria treatmentPharmacodynamic dataDP useDay 28PD studiesMalariaDay 63Strong associationPQ concentrationProphylaxis
2007
Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal P, Ouédraogo J. Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso. Clinical Infectious Diseases 2007, 45: 1453-1461. PMID: 17990228, DOI: 10.1086/522985.Peer-Reviewed Original ResearchConceptsUncomplicated Plasmodium falciparum malariaPlasmodium falciparum malariaFalciparum malariaArtemether-lumefantrineRecurrent parasitemiaUncomplicated P. falciparum malariaCombination antimalarial therapyEarly treatment failureSerious adverse eventsP. falciparum malariaDrug-resistant parasitesYears of ageMonths of ageAntimalarial regimenDihydroartemisinin-PiperaquineLumefantrine regimenAdverse eventsCombination regimensSulfadoxine-pyrimethamineRandomized comparisonTreatment failureNew regimenRecurrent malariaAntimalarial therapyTreatment groups
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply